ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tenapanor

Also written as “Tenapanor”, “AZD1722” and “KHK7791”.

Its studies are mostly in Hyperphosphatemia · Constipation · Breast Feeding · Kidney Failure, Chronic · Renal Insufficiency, Chronic, led by 2 companies.

Drug pageTenapanor: every studyAll 37 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 14, 201934 company-led studies, 2 open or runningNext primary completion: Feb 26, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ardelyx272 open or runningphase 4since Jun 14, 2019Apr 20, 2011Feb 26, 2027phase 3 · NCT07382167
Kyowa Kirinits history only70 open or runningphase 3since Feb 16, 2021Jan 29, 2019none ahead

Also a collaborator on its studies: AstraZeneca.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ardelyx only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Apr 20, 2011.

  1. Dec 2, 2015Phase 3 study in Constipation Predominant Irritable Bowel SyndromeNCT02621892 · 606 enrolled · United States
  2. Jan 11, 2016Phase 3 study in Constipation Predominant Irritable Bowel SyndromeNCT02686138 · 593 enrolled · United States
  3. Feb 3, 2016Phase 3 study in HyperphosphatemiaNCT02675998 · 219 enrolled · United States
  4. Mar 23, 2016Phase 3 study in Constipation Predominant Irritable Bowel SyndromeNCT02727751 · 312 enrolled · United States
  5. Jun 7, 20162 phase 1 studies in HealthyNCT02819687, NCT02796131
  6. Jan 19, 2018Phase 3 study in HyperphosphatemiaNCT03427125 · 1,559 enrolled · United States
  7. Jan 29, 2019Phase 3 study in HyperphosphatemiaNCT03824587 · 236 enrolled · United States
  8. Jun 14, 2019Phase 4 study in HyperphosphatemiaNCT03988920 · 172 enrolled · United States
  9. Sep 9, 2020Phase 4 study in HyperphosphatemiaNCT04549597 · 333 enrolled · United States
  10. Nov 30, 2022Phase 3 study in Irritable Bowel Syndrome With Constipation (IBS-C)NCT05643534 · 180 enrolled · United States
  11. Mar 7, 2023Phase 3 study in Irritable Bowel Syndrome With Constipation (IBS-C)NCT05905926 · 150 planned · United States
  12. Dec 17, 2023Phase 1 study in Breast FeedingNCT06203444 · 7 enrolled · United States
  13. Aug 12, 2024Phase 2 study in Irritable Bowel Syndrome With Constipation (IBS-C)NCT06553547 · 72 enrolled · United States
  14. Jan 26, 2026Phase 3 study in Chronic Idiopathic Constipation (CIC)NCT07382167 · 692 planned · United States

Ahead

  1. Feb 26, 2027Primary completion: phase 3 study in Chronic Idiopathic Constipation (CIC)NCT07382167
  2. Jul 2031Primary completion: phase 3 study in Irritable Bowel Syndrome With Constipation (IBS-C)NCT05905926

TargetBeta

SLC9A3 →read by rule
“Sodium/hydrogen exchanger 3 inhibitor”ChEMBL 37, by rule

Studies

All 27 Ardelyx leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07382167Chronic Idiopathic Constipation (CIC) · United States3RecruitingFeb 26, 2027692
NCT06553547Irritable Bowel Syndrome With Constipation (IBS-C) · United States2CompletedJul 7, 202672
NCT06203444Breast Feeding · United States1CompletedMay 30, 20247
NCT05905926Irritable Bowel Syndrome With Constipation (IBS-C) · United States3By invitationJul 2031150
NCT05643534Irritable Bowel Syndrome With Constipation (IBS-C) · United States3CompletedAug 20, 2026180
NCT04549597Hyperphosphatemia · United States4CompletedOct 13, 2021333
NCT03988920Hyperphosphatemia · United States4CompletedJun 26, 2021172
NCT03824587Hyperphosphatemia · United States3CompletedJul 17, 2019236
NCT03427125Hyperphosphatemia · United States3CompletedNov 15, 20191,559
NCT02819687Healthy1CompletedMar 201180
NCT02796131Healthy1CompletedOct 2011105
NCT02727751Constipation Predominant Irritable Bowel Syndrome · United States3CompletedOct 2017312
NCT02675998Hyperphosphatemia · United States3CompletedDec 2016219
NCT02686138Constipation Predominant Irritable Bowel Syndrome · United States3CompletedAug 2017593
NCT02621892Constipation Predominant Irritable Bowel Syndrome · United States3CompletedMar 2017606
NCT02346890Healthy · United States1CompletedApr 201316
NCT02249936Healthy · United States1CompletedFeb 201318
NCT02226783Healthy Volunteers Food Interaction Study · United States1CompletedOct 201337
NCT02140281Healthy Volunteers · United States1CompletedAug 201471
NCT02140268Healthy Volunteers · United States1CompletedAug 201465
NCT02081534Hyperphosphatemia · United States, Poland, Slovakia and more2CompletedNov 2014162
NCT02063386Healthy Volunteers · United Kingdom1CompletedMay 201426
NCT02176252Healthy Volunteer · United States1CompletedDec 201383
NCT01923428Constipation Predominant Irritable Bowel Syndrome · United States3CompletedOct 2014356
NCT01847092Renal Insufficiency, Chronic · United States2CompletedMar 2015154
NCT01764854Kidney Failure, Chronic · United States2CompletedOct 201388
NCT01340053Constipation Predominant Irritable Bowel Syndrome · United States2CompletedDec 2011186

How it is read

Names in the registry

  • “Tenapanor”, 11 entries
  • “AZD1722”, 8 entries
  • “KHK7791”, 7 entries
  • “RDX5791”, 3 entries
  • “Tenapanor 50 MG”, 1 entry

Codes read as this program: AZD1722.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.